Orange Book product · Generic (ANDA)
EPINEPHRINE
EPINEPHRINE
At a glance
Sep 06, 2024
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 06, 2024
1 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
EPINEPHRINE
Strength
EQ 30MG BASE/30ML (EQ 1MG BASE/ML)
Dosage form
SOLUTION
Route
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
TE code
AP
Application
ANDA 217192
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of EPINEPHRINE
- 2026EPINEPHRINEBrand (NDA)
NDA 220626 · BAXTER HLTHCARE CORP
- 2025EPINEPHRINEBrand (NDA)
NDA 215425 · FRESENIUS KABI USA
- 2025NEFFYBrand (NDA)
NDA 214697 · ARS PHARMS OPERATION
- 2024EPINEPHRINEBrand (NDA)
NDA 205029 · BPI LABS
- 2023ADRENALINBrand (NDA)
NDA 215875 · PH HEALTH
- 2022EPINEPHRINEBrand (NDA)
NDA 211363 · INTL MEDICATION SYS
- 2019EPINEPHRINEBrand (NDA)
NDA 209359 · HOSPIRA
- 2018PRIMATENE MISTBrand (NDA)
NDA 205920 · ARMSTRONG PHARMS
- 2018SYMJEPIBrand (NDA)
NDA 207534 · ADAMIS PHARMS CORP
- 2017AUVI-QBrand (NDA)
NDA 201739 · KALEO INC
- 2013ADRENALINBrand (NDA)
NDA 204640 · PH HEALTH
- 2012ADRENALINBrand (NDA)
NDA 204200 · PH HEALTH
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
